

ASX Announcement

23 October 2025

Q1 FY26 Quarterly Activities Report & Appendix 4C

Audeara Ltd (ASX: AUA) ('Audeara' or 'the Company') is pleased to provide the following update for the three-month period ended 30 September 2025 ('Q1 FY26').

Highlights

- ▶ Revenue¹ of \$1.52m - up 111% on the previous quarter
- ▶ Revenue increase underpinned by ongoing momentum of AUA Technology division and 99% increase in sales from Australian wholesale channel on a year-on-year basis
- ▶ Net cash outflows of \$338k, a 55% improvement on Q4 FY25 following completion of stock purchasing and R&D in the prior quarter
- ▶ Cash at bank of \$1.21m as at 30 September 2025

Financial results underpinned by strong operational momentum:

- ▶ Licensing agreement secured with Eastech (Huizhou) Co., Ltd., a wholly owned subsidiary of Eastech Holding Limited (TWSE: 5225):
 - ▷ AUA to license its proprietary hearing tech and provide development support for hearing aids under Eastech's National Medical Products Administration (NMPA) certification
 - ▷ Initial order of 1,000 hearing aid technology licence keys received from Eastech post period end with product and launch to commence in the near term
 - ▷ Audeara to benefit from sales under a third-party brand and distribution via a leading Chinese hearing aid ecommerce provider with national reach
- ▶ International footprint strengthened with distribution agreement with Eyear System Inc. to launch Auracast accessibility in Japan
- ▶ Project agreement with Ear Science Institute Australia (ESIA) to advance bone conduction listening devices, includes \$100,000 grant to Audeara
- ▶ ESIA agreement strengthened by partnership with Shokz Hear, to utilise Shokz Hear devices and AUA's technical capabilities to optimise devices for children in schools

Outlook:

- ▶ Continued focus on Australian wholesale channels and cost controls to advance path towards cashflow breakeven
- ▶ Advanced negotiations for follow on orders from major AUA Technology partners, as well as new groups and new Auracast opportunities provide high scale opportunities

¹ Any references to revenue in Q1 FY26 within this activity report, is unaudited revenue.



Management commentary

Audeara CEO and founder, Dr James Fielding said:

"The September quarter marked a strong start to FY26, delivering record quarterly revenue and clear progress across our global expansion and technology licensing strategy. Our focus remains on scaling these opportunities further to deliver tangible outcomes, highlighted by the new licensing agreement with Eastech in China and the distribution partnership with Eyear System in Japan — both of which significantly broaden our international reach and future growth potential.

"Operationally, we maintained strong momentum in our Australian wholesale channels while achieving a material reduction in net cash outflows following the completion of targeted R&D investments last quarter. This financial discipline, combined with the increasing traction of our AUA Technology partnerships, positions Audeara well to continue progressing toward cashflow breakeven.


"Looking ahead, we remain focused on building scalable, high-margin revenue streams through our expanding network of global partners and Auracast initiatives, while continuing to deliver innovative, accessible hearing solutions that improve listening experiences for people everywhere."

Financial Overview


- ▶ Revenue of \$1.52 million, marking a 111% increase on Q4 FY25
- ▶ Increased revenue underpinned by AUA Technology division, as well as 99% uplift in Australian wholesale channel orders on a year-on-year basis
- ▶ Cash receipts of \$1.22m, up 27% from \$957k in Q4 FY25
- ▶ Net operating cash outflows reduced 55% on last quarter to \$338k following completion of targeted R&D opportunities
- ▶ Payments to related parties, including directors' fees, of \$133k, in line with Q4 FY25
- ▶ Cash at bank as at 30 September 2025 of \$1.21m



Quarterly Cash Receipts vs. Net Operating Cash Usage




Annual Cash Receipts vs. Net Operating Cash Usage






Quarterly Revenue



Annual Revenue





Operational Overview

During the quarter, the Company continued to advance multiple partnership and distribution opportunities to increase its foothold in key addressable markets.

Project Collaboration with Ear Science Institute Australia and Shokz Hear

Audeara secured a project collaboration with the Ear Science Institute Australia (ESIA) to explore bone-conduction hearing solutions for use in high-need Australian communities ([ASX announcement 5 August](#)).

The initiative combines ESIA's clinical expertise and \$100,000 in funding support with Audeara's technology and product development capabilities. Activities under the collaboration will include product evaluation, stakeholder engagement, and pilot integration in educational settings.

The partnership reinforces Audeara's commitment to advancing inclusive listening technology and supporting better hearing outcomes through collaboration with leading research and health organisations.

Following the initial collaboration, the Company strengthened the partnership through a [research partnership with Shokz Hear](#), the hearing division of Shokz, leveraging Audeara's technical capabilities to optimise Shokz Hear devices for use by children in schools.

The devices were successfully demonstrated and utilised in community schools in the Pilbara in WA by the ESIA team, which led to positive feedback from students and staff. This marks the completion of the first step of developing solutions for these communities.

Licensing Agreement with Eastech (Huizhou) Co., Ltd.

Audeara entered into a licensing agreement with Eastech (Huizhou) Co., Ltd., enabling the integration of Audeara's proprietary technology into products for the Chinese medical device market ([ASX announcement 12 August](#)).

Under the agreement, Audeara will provide engineering services and technical support to assist with NMPA (China) certification and product commercialisation. The devices will be sold under a third-party brand and distributed via major Chinese e-commerce platforms including Tmall, JD.com and Pinduoduo.

This collaboration represents a significant step forward in Audeara's global expansion strategy, extending the reach of its technology to new markets and reinforcing its position as a leader in innovative listening solutions.

Subsequent to the end of the period, the Company secured its maiden order from Eastech for 1,000 hearing aid licence keys. This marked the first commercial traction with the counterparty and another important step in Audeara's entry into the Chinese hearing aid market ([ASX announcement 15 October](#)).

Clinico Inc. Retail Channel Expansion

Earlier in the year, strategic partner and customer Clinico launched the Clinico Sound CS1, a true-wireless personal hearing device developed by Audeara for Clinico. Building on its position as a market leader in hearing and sleep health across Taiwan, Clinico is now expanding into



shopping centre retail as part of its new growth strategy, with the CS1 positioned as its flagship product in this next phase.

The CS1 features three listening modes — *Focus, Full Listening and Voice Focus* — along with environmental sound amplification. Its design bridges health technology and everyday consumer use, supporting Clinico's goal to make hearing and wellness solutions more accessible through both clinical and retail environments.

This expansion marks an important step for both Clinico and Audeara, strengthening Audeara's presence in Asia and demonstrating the versatility of its product development capabilities across new markets and applications.

Japanese Market Distribution Agreement

Post period end, Audeara further strengthened its international footprint securing a non-exclusive distribution agreement with Eyear System Inc., a leading Tokyo-based audiology and hearing solutions company, to launch its Auracast-enabled products in Japan ([ASX announcement 14 October](#)).

The partnership will introduce Audeara's BT-LE Audio Transceiver and BT-03 Audio Broadcaster into the Japanese market, supported by an initial minimum order of 100 units and a tiered pricing structure for future orders. The collaboration includes joint efforts on local certification and market launch to accelerate product availability in Japan's advanced hearing-health sector.

Demonstrating the strength of the partnership, Audeara and Eyear System will jointly exhibit at the Makuhari Messe trade show in Chiba, Japan (19–21 November 2025), showcasing Auracast accessibility solutions to key healthcare and technology stakeholders across Asia.

This agreement represents a significant milestone in Audeara's global expansion strategy, following new partnerships in Taiwan, the United States, and Europe.

Auracast™ Initiatives

Expansion of inclusive listening solutions continued during the period, with Audeara's Auracast-enabled devices used to deliver more connected experiences across education, the arts and global advocacy. Key highlights include:

- ▶ **Bluetooth Special Interest Group (Bluetooth SIG):** The global body responsible for developing Bluetooth standards and driving innovation in wireless audio technology invited Dr James Fielding to appear on its podcast to discuss how Auracast™ provides people of all listening abilities with greater choice and control over their listening experience.
- ▶ **The University of Queensland:** More than 30 lecture rooms across three campuses are now Auracast-enabled, helping make learning environments more accessible for students of all hearing abilities.
- ▶ **Brisbane Symphony Orchestra:** **4MBS Classic FM** provided a broadcast-quality signal for Auracast™ transmission during a live performance of Elgar's *The Dream of Gerontius* at Brisbane City Hall, presented by the Brisbane Symphony Orchestra with the Brisbane



Chorale and Canticum Chamber Choir. The initiative showcased how Auracast can enhance live performances by delivering an immersive and accessible listening experience for audiences.

Together, these initiatives highlight Audeara's leadership in advancing inclusive listening and reinforce the company's belief that listening helps us feel connected.

Awards Recognition

Throughout the quarter, Audeara received multiple award nominations, and subsequent to the end of the period has received the following honours:

- ▶ **Premier of Queensland's Export Awards 2025:** Winner of the *Small Business* award; Runner-up in the *International Health* award.
- ▶ **Hong Kong-Australia Business Association Queensland Chapter Business Awards:** Winner of the *Best Initiative* award.
- ▶ **Australia's International Good Design Awards:** Winner of the *Product Design (Consumer Electronics)* for Audeara Buds.
- ▶ **2025 Lord Mayor's Business Awards:** Finalist in the *Business Transformation* and *International Business* award categories (winner to be announced in November).

These accolades highlight Audeara's continued growth and leadership as an Australian innovator making a meaningful global impact in hearing health.

Outlook

In the current quarter and beyond, Audeara remains focused on further strengthening its Australian wholesale channels, while maintaining disciplined cost controls as it advances towards its stated strategy of cashflow breakeven. The Company will also continue to advance negotiations with key AUA Technology partners for additional purchase orders, and pursue initiatives to broaden Auracast uptake. These opportunities present significant avenues for scalable growth both domestically and internationally.

This announcement has been authorised by the Board of Audeara Limited.

For more information please visit, audeara.com.

CORPORATE & MEDIA ENQUIRIES

Dr James Fielding

Managing Director and Chief Executive Officer

james.fielding@audeara.com

INVESTOR ENQUIRIES

Henry Jordan

Six Degrees Investor Relations

henry.jordan@sdir.com.au



ABOUT AUDEARA

Feel connected, your way.

Audeara Limited (ASX: AUA) is a global hearing health leader specialised in innovative listening solutions for people with hearing challenges.

We are passionate about redefining hearing health, with a particular focus on delivering products that provide world-class tailored listening experiences.

We care about connecting people with experiences that bring them joy - whether that's watching a favourite TV show, FaceTiming family or listening to music with confidence.

All Audeara products are purposefully designed and engineered in Australia with precision detail and state-of-the-art technology. Each product delivers optimum listening experiences to enhance quality of life for people of all ages and abilities.

Audeara sells its products through distributors and resellers in Australia, Europe, Asia and North America, and through e-commerce channels.



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AUDEARA LIMITED

ABN

27 604 368 443

Quarter ended (“current quarter”)

30 SEPTEMBER 2025

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
1	Cash flows from operating activities		
1.1	Receipts from customers	1,229	1,229
1.2	Payments for		
(a)	research and development	(143)	(143)
(b)	product manufacturing and operating costs	(583)	(583)
(c)	advertising and marketing	(44)	(44)
(d)	leased assets	(1)	(1)
(e)	staff costs	(600)	(600)
(f)	administration and corporate costs	(234)	(234)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	38	38
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (refund of rental bond)	-	-
1.9	Net cash from / (used in) operating activities	(338)	(338)

2	Cash flows from investing activities		
2.1	Payments to acquire or for:		
(a)	entities	-	-
(b)	businesses	-	-
(c)	property, plant and equipment	-	-
(d)	investments	-	-
(e)	intellectual property	-	-
(f)	other non-current assets	-	-
2.2	Proceeds from disposal of:		
(a)	entities	-	-
(b)	businesses	-	-
(c)	property, plant and equipment	-	-
(d)	investments	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
(e)	intellectual property	-	-
(f)	other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-
3	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	195	195
3.6	Repayment of borrowings	(57)	(57)
3.7	Transaction costs related to loans and borrowings	(7)	(7)
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	131	131
4	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,422	1,422
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(338)	(338)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	131	131
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	1,215	1,215

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

5 Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	1,215	1,422
5.2 Call deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,215	1,422
6 Payments to related parties of the entity and their associates		Current quarter \$A'000
6.1 Aggregate amount of payments to related parties and their associates included in item 1		133
6.2 Aggregate amount of payments to related parties and their associates included in item 2		-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		
7 Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	1,115	1,093
7.2 Credit standby arrangements	-	-
7.3 Other (insurance premium funding)	50	50
7.4 Total financing facilities	1,165	1,143
7.5 Unused financing facilities available at quarter end		22
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
<p>7.1: (i) Short term loan facility with Sturt Capital Pty Ltd against the anticipated R&D Tax Incentive rebate for FY2025. The loan facility has an establishment fee of 1.5%, bears interest of 1.33% per month with a repayment date which is earlier of the date of receipt of the 2025 R&D Tax Incentive from the Australian Taxation Office and 31 December 2025. Principal outstanding at 30 September 2025 was \$898,737.</p> <p>(ii) Short term loan facility with Sturt Capital Pty Ltd against the anticipated R&D Tax Incentive rebate for FY2026 Q1. The loan facility has an establishment fee of 1.5%, bears interest of 1.33% per month with a repayment date which is earlier of the date of receipt of the 2026 R&D Tax Incentive from the Australian Taxation Office and 31 December 2026. Principal outstanding at 30 September 2025 was \$194,684.</p> <p>(iii) Westpac Banking Corporation credit card facility, secured rolling line of credit for \$21,730 at 20.24% interest on unpaid balances</p> <p>7.3: Hunter Premium Funding, unsecured 10-month loan fully drawn in April 2025 for \$127,915.82 to fund insurance premiums. Principal outstanding at 30 September 2025 was \$50,094. The loan is repayable in monthly instalments at a flat annualised interest rate of approximately 5.6%.</p>		

8 Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(338)
8.2 Cash and cash equivalents at quarter end (item 4.6)	1,215
8.3 Unused finance facilities available at quarter end (item 7.5)	22
8.4 Total available funding (item 8.2 + item 8.3)	1,237
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	3.7
<p><i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i></p>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
N/A	
<p><i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i></p>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 23 October 2025

Authorised by: By the Board
 (Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.